Private Equity, VC & Investor
Creandum vs Rubicon VC
Structured technology and market comparison · 2026
Direct Feature Comparison
Creandum · vs · Rubicon VCEarly-stage technology venture capital firm supporting international founder growth.
Early-stage venture capital for software and internet companies.
Analyze all overlapping signals and tech stacks for Creandum and Rubicon VC
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Creandum and Rubicon VC?
When comparing Creandum and Rubicon VC, both platforms operate within the Private Equity, VC & Investor ecosystem. Creandum is positioned as Early-stage technology venture capital firm supporting international founder growth, whereas Rubicon VC focuses on Early-stage venture capital for software and internet companies. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Creandum and Rubicon VC?
When evaluating Creandum and Rubicon VC, enterprise buyers also consider other platforms in Private Equity, VC & Investor. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Creandum and Rubicon VC compare?
Creandum is headquartered in United Kingdom (founded in 2003) with 50–200 employees. Rubicon VC is based in United States (founded in 2013) with 10–49 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Creandum vs Rubicon VC
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Creandum
Recent Signals
- ·EU-Startups (European Venture)Financials
Creandum closes €668M fund for early-stage startups
Stockholm-based venture capital firm Creandum has closed its largest fund to date, Creandum VIII, at €668 million ($750 million), surpassing its previous €500 million ($560 million) Fund VII. The fund will support approximately 30 early-stage investments from pre-Seed to Series A over the next two years, with half the capital allocated to new investments and the rest for follow-on rounds. Creandum is focusing on AI-driven opportunities, having recently invested in startups like Lovable, Olix, Modal, and Black Forest Labs. The firm has opened a new office in San Francisco, tripled its team there in the past year, and plans to expand its US presence while maintaining a generalist strategy. The fund secured commitments from about 30 institutional investors across Europe and the US.
- Creandum closed its largest fund, Creandum VIII, at €668 million ($750 million), up from €500 million Fund VII.
- The fund will support approximately 30 investments from pre-Seed to Series A, with half for new investments and half for follow-ons.
- The fund focuses on AI, with portfolio companies including Lovable, Olix, Modal, and Black Forest Labs.
- ·EU-Startups (European Venture)AI in Enterprise
London's Ares Intelligence Raises €2.9M for AI Adoption Platform
London-based Ares Intelligence, a startup developing an evidence-based platform for AI transformation, has raised €2.9 million (£2.48 million) in a funding round led by Creandum and Lakestar, with participation from angel investors connected to Google DeepMind. The platform uses an AI interviewer to conduct confidential voice conversations with employees in over 70 languages, generating a prioritised roadmap for AI adoption within weeks. Founded in 2026 by Matt Falconer and Alfie Ranstead, the company addresses the challenge of where to start with AI automation. Ares counts enterprise customers across Europe and the US, including Tremonia, a Mercedes-Benz spin-out, which identified over 400 hours of manual work savings per month. The new capital will support expansion and bring its workforce intelligence approach to more businesses.
- Ares Intelligence raised €2.9 million (£2.48 million) in funding.
- The round was backed by Creandum and Lakestar, with participation from angels connected to Google DeepMind.
- The platform uses an AI interviewer to collect employee insights in over 70 languages.
- ·Tech.eu (European Tech & Deals)AI in Drug Development
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
- Atlas Bio raised a $10M Seed round led by Creandum, plus a $2.5M pre-Seed round led by First Momentum Ventures and LEA Partners, totaling $12.5M.
- The company's AI model is trained on roughly 2 million RNA readouts from human tissue.
- Atlas Bio is working with a top 10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow.
Rubicon VC
Recent Signals
- ·SEC APIfinancials
6-K Financial Filing Analysis for Rubicon VC (2026-10-28)
On October 28, 2026, Rubico Inc. filed a Form 6-K reporting the adoption and filing of Articles of Amendment to its Amended and Restated Articles of Incorporation with the Registrar of Corporations of the Republic of the Marshall Islands. Concurrently, the registrant issued a press release (Exhibit 99.1) detailing the corporate actions associated with these charter amendments. The filing formalizes structural changes to the company's governing corporate charter, signed by Chief Financial Officer Nikolaos Papastratis.
- Rubico Inc. filed Articles of Amendment to its Amended and Restated Articles of Incorporation in the Republic of the Marshall Islands on October 28, 2026.
- A concurrent press release was issued on October 28, 2026, and incorporated by reference as Exhibit 99.1.
- The filing was executed by Chief Financial Officer Nikolaos Papastratis under SEC Commission File Number 001-42684.
- ·SEC APIfinancials
6-K Financial Filing Analysis for Rubicon VC (2026-10-15)
Rubico Inc. has executed an amendment to its July 27, 2026 related-party share purchase agreement with TOP Ships Inc. regarding the acquisition of Roman Shark V Inc., which holds a shipbuilding contract for a 47,499 dwt MR chemical/product oil tanker. Under the updated terms agreed on September 30, 2026, the maturity for the remaining $3.7 million balance of the total $6.5 million purchase price—$2.8 million having already been paid in cash—was deferred from September 30, 2026, to October 31, 2026. Additionally, Rubico secured the option to settle this outstanding obligation either in cash or via newly issued Series G Convertible Preferred Shares.
- Rubico amended its share purchase agreement with related party TOP Ships Inc., extending the maturity date of the outstanding $3.7 million balance from September 30, 2026, to October 31, 2026.
- The total acquisition price for Roman Shark V Inc. is $6.5 million, with $2.8 million previously settled in cash.
- The amendment grants Rubico the election to satisfy the remaining $3.7 million in cash or through newly issued Series G Convertible Preferred Shares.
- ·SEC APIfinancials
6-K Financial Filing Analysis for Rubicon VC (2026-10-19)
Rubico Inc. entered into a Securities Purchase Agreement on October 16, 2026, with an institutional investor to issue Senior Convertible Notes and warrants across two tranches. On October 19, 2026, the company closed the initial tranche, receiving gross proceeds of $8.50 million in exchange for $9,444,444 in principal amount of Senior Convertible Notes, accompanying 5-year warrants to purchase $9,444,444 of common shares, and commitment shares or pre-funded warrants equal to 5% of the principal amount. A potential second tranche could raise an additional $5,555,556 in notes subject to specific closing conditions, including a minimum share price of $1.00 and trading volume thresholds. The 12-month convertible notes carry an 8.0% annual interest rate if paid in cash (10.0% if paid in shares) and feature a fixed conversion price of $0.3646 or an alternate floating conversion price at an 85% discount to VWAP with a $0.10 floor. Net proceeds will fund working capital. Maxim Group LLC served as the exclusive placement agent for a 6.0% cash fee.
- Rubico Inc. closed the initial tranche of a financing agreement on October 19, 2026, raising $8,500,000 against $9,444,444 principal amount of Senior Convertible Notes, 5-year warrants, and a 5% commitment share fee.
- The Senior Convertible Notes mature in 12 months (extendable to 18 months with a 5% principal step-up), pay 8.0% cash interest (10.0% in shares), and convert at a fixed price of $0.3646 or an alternate conversion price of 85.0% of the lowest 10-day VWAP (subject to a $0.10 floor).
- A potential second closing of $5,555,556 in notes and warrants is contingent on the common shares trading at or above $1.00 with average daily trading volume exceeding $200,000, among other conditions.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Creandum and Rubicon VC share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks